WBI Investments LLC Buys Shares of 3,826 Cencora, Inc. $COR

WBI Investments LLC purchased a new position in shares of Cencora, Inc. (NYSE:COR) during the 2nd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm purchased 3,826 shares of the company’s stock, valued at approximately $1,147,000.

A number of other hedge funds have also recently modified their holdings of the business. Atlantic Edge Private Wealth Management LLC raised its holdings in Cencora by 70.0% in the 2nd quarter. Atlantic Edge Private Wealth Management LLC now owns 85 shares of the company’s stock worth $25,000 after purchasing an additional 35 shares during the period. Costello Asset Management INC bought a new position in shares of Cencora in the first quarter worth about $28,000. University of Texas Texas AM Investment Management Co. bought a new position in shares of Cencora in the first quarter worth about $39,000. Caitong International Asset Management Co. Ltd purchased a new position in shares of Cencora during the 2nd quarter valued at about $61,000. Finally, ANTIPODES PARTNERS Ltd bought a new position in shares of Cencora during the 2nd quarter valued at approximately $61,000. Institutional investors own 97.52% of the company’s stock.

Insider Activity at Cencora

In related news, Chairman Steven H. Collis sold 31,350 shares of the business’s stock in a transaction on Tuesday, September 16th. The shares were sold at an average price of $289.86, for a total value of $9,087,111.00. Following the sale, the chairman owned 305,913 shares in the company, valued at approximately $88,671,942.18. The trade was a 9.30% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which is accessible through this hyperlink. Also, CEO Robert P. Mauch sold 5,097 shares of the company’s stock in a transaction on Monday, October 20th. The shares were sold at an average price of $326.80, for a total transaction of $1,665,699.60. Following the sale, the chief executive officer directly owned 37,940 shares in the company, valued at approximately $12,398,792. The trade was a 11.84% decrease in their position. The SEC filing for this sale provides additional information. Insiders have sold a total of 41,544 shares of company stock valued at $12,230,941 in the last 90 days. 10.80% of the stock is currently owned by company insiders.

Cencora Price Performance

Shares of NYSE:COR opened at $365.22 on Tuesday. The firm has a market cap of $70.81 billion, a price-to-earnings ratio of 37.57, a P/E/G ratio of 1.56 and a beta of 0.63. The firm has a fifty day moving average price of $322.71 and a 200 day moving average price of $302.76. Cencora, Inc. has a fifty-two week low of $223.92 and a fifty-two week high of $369.00. The company has a debt-to-equity ratio of 3.64, a quick ratio of 0.53 and a current ratio of 0.90.

Cencora (NYSE:COR) last announced its quarterly earnings results on Wednesday, November 5th. The company reported $3.84 EPS for the quarter, topping the consensus estimate of $3.79 by $0.05. The business had revenue of $83.73 billion for the quarter, compared to analysts’ expectations of $83.36 billion. Cencora had a net margin of 0.60% and a return on equity of 267.36%. The business’s quarterly revenue was up 5.9% compared to the same quarter last year. During the same quarter in the previous year, the company earned $3.34 EPS. Cencora has set its FY 2026 guidance at 17.450-17.75 EPS. As a group, sell-side analysts expect that Cencora, Inc. will post 15.37 earnings per share for the current fiscal year.

Cencora Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, December 1st. Shareholders of record on Friday, November 14th will be issued a dividend of $0.60 per share. The ex-dividend date is Friday, November 14th. This represents a $2.40 annualized dividend and a yield of 0.7%. This is a boost from Cencora’s previous quarterly dividend of $0.55. Cencora’s dividend payout ratio (DPR) is 30.19%.

Analyst Ratings Changes

A number of equities research analysts have commented on the stock. UBS Group raised their target price on shares of Cencora from $380.00 to $415.00 and gave the stock a “buy” rating in a research note on Friday, November 7th. Evercore ISI set a $400.00 price objective on shares of Cencora and gave the company an “outperform” rating in a research report on Thursday, November 6th. Wells Fargo & Company lifted their target price on shares of Cencora from $354.00 to $405.00 and gave the company an “overweight” rating in a research note on Tuesday, November 11th. Mizuho upped their target price on shares of Cencora from $340.00 to $380.00 and gave the stock an “outperform” rating in a report on Thursday, November 6th. Finally, JPMorgan Chase & Co. increased their price target on Cencora from $344.00 to $417.00 and gave the stock an “overweight” rating in a research note on Tuesday, November 11th. Nine equities research analysts have rated the stock with a Buy rating and three have issued a Hold rating to the company’s stock. According to data from MarketBeat, Cencora has a consensus rating of “Moderate Buy” and an average price target of $371.09.

Cencora Company Profile

Cencora, Inc sources and distributes pharmaceutical products. The company's U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers; provides pharmacy management, staffing, and other consulting services; supply management software to retail and institutional healthcare providers; packaging solutions to various institutional and retail healthcare providers; clinical trial support, product post-approval, and commercialization support services; data analytics, outcomes research, and additional services for biotechnology and pharmaceutical manufacturers; pharmaceuticals, vaccines, parasiticides, diagnostics, micro feed ingredients, and other products to the companion animal and production animal markets; and sales force services to manufacturers.